Oncopeptides AB

Oncopeptides operates with a negative equity position of -58.89 million SEK and a total debt of 139.39 million SEK, resulting in a debt-to-equity ratio of -2.37, indicating a highly leveraged capital structure. The company's liquidity position is characterized by a current ratio of 2.61, suggesting it can cover its short-term liabilities with its current assets, but its negative net cash position raises concerns about its ability to fund operations without external financing. Profitability metrics reveal a challenging financial landscape for Oncopeptides. The company reported a net loss of 249.58 million SEK and an operating loss of 224.65 million SEK, with a return on equity of 4.24% and a negative return on assets of -1.84%. These figures are below the industry median for biotechnology firms, which typically exhibit higher returns during growth phases. Geographically, Oncopeptides' revenue is concentrated in a limited number of markets, with the majority of its sales derived from oncology treatments in Europe and the United States. The company's exposure to a narrow geographic footprint increases its vulnerability to regional economic downturns and regulatory changes. The company's growth trajectory is mixed. While revenue for the latest period was 71.12 million SEK, analyst estimates project a significant increase to 184 million SEK in the next fiscal year. However, the company's operating and net losses have widened, and free cash flow remains negative at -239.92 million SEK, indicating ongoing operational challenges. Risk factors include a high liquidity risk due to negative net cash and a medium credit risk from its leveraged position. The company's dilution risk is currently low, but its reliance on external financing could increase this risk in the near term. The company has not issued new shares recently, and no dilution adjustments have been applied to its valuation metrics. Recent events include a consistent price target of 2.64 SEK from analysts, despite a significant decline in the company's stock price. The company's earnings per share (EPS) have deteriorated from -1.04 SEK to an estimated -0.35 SEK, reflecting ongoing financial pressures.